Plant Cell Culture Media Patents: Top Companies & Trends 2026
Plant Cell Culture Media Formulation Patents: Who Files, What They Claim
Top 5 filers hold 48.0% of the field. 3,218 of 6,699 records in scope sit with just five assignees, so freedom-to-operate searches concentrate fast around a small set of names. Annual filings peaked in 2017 at 265 and have since settled into a lower, comparatively stable band. Using only the years that can be treated as complete, 2021 (118) to 2024 (121) moved +3% — essentially flat. Years after 2024 will continue to fill in as publications catch up, so treat any apparent drop in 2025-2026 as an artefact of lag, not a real fall-off in filing activity.
- 1PIONEER HI BREED INTERNATIONAL INC16.8%
- 2MONSANTO TECHNOLOGY LLC12.7%
- 3STINE SEED FARM INC7.4%
- 4SYNGENTA PARTICIPATIONS AG6.7%
- 5DOW AGROSCIENCES LLC4.3%
See the full plant cell culture media formulation analysis in Eureka
- The complete ranking, not just the top five
- Every IPC branch with its share of the corpus
- The most-cited records, and where claim space is still thin
Common questions on this landscape
Who holds the most patents in plant cell culture media formulation?
One assignee leads with 1,127 of the 6,699 records in scope, a wide margin over the fifth-ranked filer at 291 and the tenth at 142. The top 5 assignees together hold 48.0% of all records, and the top 10 hold 61.2%. This is a top-heavy field: most of the enforceable IP sits with a small number of long-established agricultural biotech portfolios rather than being spread evenly across many smaller filers.
Is patent filing in this field growing or slowing down?
Filing peaked in 2017 at 265 records and settled lower afterward, but it has not continued to decline. Comparing the last two years that can be treated as complete, 2021 (118) and 2024 (121), filings rose 3%. Because patent publication lags filing by roughly 18 months, the lower counts shown for 2025 and 2026 in any trend chart understate the true filing volume for those years and should not be read as a slowdown.
What does EP3283092B1 actually cover?
EP3283092B1, filed by VYTRUS BIOTECH, S.L. and published 2026-04-29, covers a cell-free supernatant derived from plant cell culture suspension, claimed for rejuvenation and wound-healing activity on skin cells. It is a cosmetic and dermal-application patent built on plant cell culture technique rather than an agricultural trait or seed patent, which distinguishes it from most of the highest-cited records in this dataset.
Disclaimer. This analysis is based on Patsnap Eureka data drawn from a limited snapshot of global patent records and is provided for general information and reference only. Patent data carries inherent limitations — recent filings are under-counted because of publication lag, counts may be on a record or family basis, classification and applicant-name data may contain errors or duplicates, and the underlying search query defines the scope shown — so the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing here is an exhaustive prior-art, novelty, freedom-to-operate or validity search, nor does it constitute legal, financial or professional advice, and it should not be relied upon as such. Verify independently and review with qualified patent and legal professionals before acting on it.
Method: Filing trend and technology composition. Derived from a Patsnap search on Plant Cell Culture Media Formulation covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish. Every share divides by all records in scope. Data: Patsnap Eureka. See the full landscape report.